Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

20151,570 citationsJournal Articlebronze Open Access

Authors

Nicholas C. Turner · Royal Marsden Hospital

Jungsil Ro · National Cancer Center

Fabrice André · Institut Gustave Roussy

Sherene Loi · University of Melbourne

Sunil Verma · Sunnybrook Health Science Centre

Hiroji Iwata · Aichi Cancer Center

Nadia Harbeck

Abstract

Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.).

Topics & Keywords

Advanced Breast Cancer Therapies Cancer-related Molecular Pathways HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 3, pp. 209-219

DOI: 10.1056/nejmoa1505270

Field-Weighted Citation Impact: 142.08